Detailansicht

Wissensnetz

Person

Ute Ganswindt (1967-)

Name	Ute Ganswindt
Zeit	1967- (Lebensdaten)
Variante	Ute Maria Ganswindt
Weitere Angaben	Diss. Medizinische Fakultät
Datensatztyp	Person
GND-Nummer	122619927
Datensatz-ID	122619927
Beteiligt an alle anzeigen Prostate cancer and elective nodal radiation therapy for cN0 and pN0—a never ending story? : : Recommendations from the prostate cancer expert panel of the German Society of Radiation Oncology (DEGRO) Dynamic intrafractional position monitoring with implanted fiducial markers for enhanced accuracy in radiotherapy of prostate cancer A novel 2-metagene signature to identify high-risk HNSCC patients amongst those who are clinically at intermediate risk and are treated with PORT Moderately hypofractionated radiotherapy as definitive treatment for localized prostate cancer: Pattern of practice in German-speaking countries : A survey of the Prostate Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO) and the Working Party on Radiation Oncology of the German Cancer Society (DKG-ARO) Interdisziplinärer Expertenkonsensus zu Innovationen der bildgebenden Diagnostik und radionuklidbasierten Therapien des fortgeschrittenen Prostatakarzinoms A multi-institutional analysis of prostate cancer patients with or without 68Ga-PSMA PET/CT prior to salvage radiotherapy of the prostatic fossa A multi-institutional analysis of prostate cancer patients with or without 68Ga-PSMA PET/CT prior to salvage radiotherapy of the prostatic fossa Early senescence and production of senescence-associated cytokines are major determinants of radioresistance in head-and-neck squamous cell carcinoma ESTRO ACROP guideline for target volume delineation of skull base tumors Interdisziplinärer Expertenkonsensus zu Innovationen der bildgebenden Diagnostik und radionuklidbasierten Therapien des fortgeschrittenen Prostatakarzinoms = Interdisciplinary expert consensus on innovations in imaging diagnostics and radionuclide-based therapies for advanced prostate cancer Ultrahypofractionation of localized prostate cancer : : statement from the DEGRO working group prostate cancer Ultrahypofractionation of localized prostate cancer : Statement from the DEGRO working group prostate cancer Definition and validation of a radiomics signature for loco-regional tumour control in patients with locally advanced head and neck squamous cell carcinoma First statement on preparation for the COVID-19 pandemic in large German Speaking University-based radiation oncology departments Outcome after 68Ga-PSMA-11 versus choline PET-based salvage radiotherapy in patients with biochemical recurrence of prostate cancer: a matched-pair analysis PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives Time for standardization of SBRT planning through large scale clinical data and guideline-based approaches Planning benchmark study for SBRT of early stage NSCLC : Results of the DEGRO Working Group Stereotactic Radiotherapy Bayesian cure rate modeling of local tumor control: evaluation in stereotactic body radiation therapy for pulmonary metastases Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy Topische Anwendung von Prostaglandin E2 zur Behandlung der oralen Mukositis unter hochdosierter Chemotherapie

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Ute Ganswindt (1967-)

Prostate cancer and elective nodal radiation therapy for cN0 and pN0—a never ending story? : : Recommendations from the prostate cancer expert panel of the German Society of Radiation Oncology (DEGRO)

Dynamic intrafractional position monitoring with implanted fiducial markers for enhanced accuracy in radiotherapy of prostate cancer

A novel 2-metagene signature to identify high-risk HNSCC patients amongst those who are clinically at intermediate risk and are treated with PORT

Interdisziplinärer Expertenkonsensus zu Innovationen der bildgebenden Diagnostik und radionuklidbasierten Therapien des fortgeschrittenen Prostatakarzinoms

A multi-institutional analysis of prostate cancer patients with or without 68Ga-PSMA PET/CT prior to salvage radiotherapy of the prostatic fossa

A multi-institutional analysis of prostate cancer patients with or without 68Ga-PSMA PET/CT prior to salvage radiotherapy of the prostatic fossa

Early senescence and production of senescence-associated cytokines are major determinants of radioresistance in head-and-neck squamous cell carcinoma

ESTRO ACROP guideline for target volume delineation of skull base tumors

Interdisziplinärer Expertenkonsensus zu Innovationen der bildgebenden Diagnostik und radionuklidbasierten Therapien des fortgeschrittenen Prostatakarzinoms = Interdisciplinary expert consensus on innovations in imaging diagnostics and radionuclide-based therapies for advanced prostate cancer

Ultrahypofractionation of localized prostate cancer : : statement from the DEGRO working group prostate cancer

Ultrahypofractionation of localized prostate cancer : Statement from the DEGRO working group prostate cancer

Definition and validation of a radiomics signature for loco-regional tumour control in patients with locally advanced head and neck squamous cell carcinoma

First statement on preparation for the COVID-19 pandemic in large German Speaking University-based radiation oncology departments

Outcome after 68Ga-PSMA-11 versus choline PET-based salvage radiotherapy in patients with biochemical recurrence of prostate cancer: a matched-pair analysis

PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives

Time for standardization of SBRT planning through large scale clinical data and guideline-based approaches

Planning benchmark study for SBRT of early stage NSCLC : Results of the DEGRO Working Group Stereotactic Radiotherapy

Bayesian cure rate modeling of local tumor control: evaluation in stereotactic body radiation therapy for pulmonary metastases

Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy

Topische Anwendung von Prostaglandin E2 zur Behandlung der oralen Mukositis unter hochdosierter Chemotherapie